ĐÁNH GIÁ KẾT QUẢ BƯỚC ĐẦU ĐIỀU TRỊ ALECTINIB TRÊN BỆNH NHÂN UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ GIAI ĐOẠN IV CÓ ĐỘT BIẾN GEN ALK

Abstract

Objectives: Describe clinical characteristics, subclinical clinical patients with non-small cell cancer stage IV with gene mutations ALK at K Hospital and evaluate the initial results. Patients and Methods: Research description, vertical monitoring with convenient samples including 26 patients with NSCLC phase IV, with mutations ALK, treatment at K Hospital from 1/2023 - 11/2023 equal to alectinib. Results: The study was conducted in 26 patients. The average age is 50 years old, the rate of men 34.6%, the rate of women 63.4%, most patients have the total index of ECOG PS 0 and 1, accounting for 88.4%; ECOG PS 2 and 3 accounts for 11.6%, the brain, lungs and pleura are the most common metastatic position, accounting for 34,6%. Determining the mutation based on NGS method, immunohistochemistry and Fish method accounting for 80,8%, 15,4%, 3,8%respectively. The response ratio: The response rate is completely 7,7%, partially responded to 76,9%, stable disease is 15,4%, there is no case of progression. The brain response is 66,7%, the ratio of disease control in the brain is 100%. Common side effects are increased liver enzymes accounting for 19,2% of which 1 patient increases liver enzymes with 3 -battle 3,8%.